-       Report 
   - April 2023
    -  70 Pages 
    Canada
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - April 2023
    -  85 Pages 
    Europe
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - April 2023
    -  125 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - January 2025
    -  83 Pages 
    Vietnam
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - August 2024
    -  80 Pages 
    Japan
   
   From       €3146EUR$3,500USD£2,759GBP 
                 -       Report 
   - April 2024
    -  188 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                  -       Report 
   - February 2024
    -  360 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - August 2024
    -  150 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                -       Report 
   - September 2024
    -  163 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                -       Report 
   - April 2025
    -  126 Pages 
    
   From       €3101EUR$3,450USD£2,720GBP 
                -       Report 
   - July 2024
    -  150 Pages 
    Global
   
   From       €4000EUR$4,450USD£3,508GBP 
                -       Report 
   - December 2023
    -  140 Pages 
    Global
   
   From       €4000EUR$4,450USD£3,508GBP 
                -       Report 
   - October 2024
    -  43 Pages 
    Global
   
   From       €3591EUR$3,995USD£3,149GBP 
                -       Report 
   - November 2022
    -  68 Pages 
    Global
   
   From       €3141EUR$3,495USD£2,755GBP 
                -       Report 
   - October 2024
    -  127 Pages 
    Global
   
   From       €3595EUR$4,000USD£3,153GBP 
                -       Report 
   - November 2020
    -  199 Pages 
    Global
   
        €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - February 2024
    -  79 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - November 2023
    -  113 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
                -       Report 
   - October 2023
    -  134 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
             
         The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha    agonists, carbonic anhydrase inhibitors, and cholinergic agonists.
Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less   Read more